Fig. 1 · Structure
Documents & Downloads
Cantuzumab mertansine
CanAg ADC
Cantuzumab mertansine is an antibody-drug conjugate (ADC) that combines the cytotoxic maytansine derivative DM1 with the humanized monoclonal antibody huC242, targeting CanAg. This compound exhibits significant cytotoxic activity specifically against colon cancer cells and demonstrates broad antitumor efficacy across various CanAg-positive human tumor xenograft models. Its application in research includes studies focused on targeted cancer therapy and the assessment of antitumor effects in specific malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 400010-39-1 |
| Applications | CanAg ADC |
| Molecular Weight | 150000 (average) |
| Synonyms | SB-408075; huC242-DM1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.